ABL will carry out cGMP production of rhFSH for Trophogen, while Microtest will manufacture ImmusanT’s celiac disease vaccine.
Cellzome-led consortium will characterize stem cells through protein fingerprints that predict behavior changes.
Firm maintains acquisition will allow transition from technology platform operation to specialty pharma company.
Firm’s instruments boost Pall’s process monitoring and protein research offerings.
Cervista HTA system automates DNA extraction and detection procedures.
Maryland firm announced birth of rhFVII transgenic rabbits at Chinese subsidiary.
Firm will use protein engineering technology to shorten enzyme discovery time.
Nansha site now houses additional capacity for small-scale API production.
Firms will help governments construct and run facilities to manufacture vaccines and biopharmaceuticals such as insulin.
Please wait while you are redirected to the right page...